初发系统性红斑狼疮患者调节性T细胞和Th17细胞的检测及意义  

Clinical significance of regulatory T cells and Th17 cells in the patients with new-onset systemic lupus erythematosus

作　　者：马纪林[1] 刘小贤[1] 汪卫[1] 郑红霞[1] 蔡龙[1] 施华萍[1] 周红娟[1] 于健宁[1] 

机构地区：[1]杭州市红十字会医院风湿免疫肾脏科,310003

出　　处：《浙江医学》2013年第20期1787-1790,共4页Zhejiang Medical Journal

基　　金：国家自然科学基金(81274161;81001307);浙江省自然科学基金(Y2090918);浙江省医药卫生科学研究基金计划项目(2012RCA046;2011KYA137;2007A162);杭州市科技发展计划项目(20080333Q28;20110733Q15;20110833B26)

摘　　要：目的观察初发系统性红斑狼疮(SLE)患者外周血调节性T细胞(Treg)和Th1 7细胞的变化,探讨其临床意义。方法检测15例初发SLE患者(活动组1 1例,非活动组5例)及10例健康对照者(对照组)的外周血CD4^+CD25^(high)Treg、Th17细胞占CD4^+的比例,分析两种细胞的比率与疾病活动指数(SLEDAI)的相关性。结果初发SLE患者外周血CD4^+CD25^(high)Treg和Th17细胞的比例与对照组相比,差异无统计学意义(P>0.05),与SLEDAI无相关性(均P>0.05)。CD4^+CD25^(high)T细胞与Th17细胞的比率在活动组患者下降尤为明显(P<0.05),且与SLEDAI呈明显的负相关(P<0.05)。结论初发的活动性SLE患者外周血Treg与Th17细胞的比率明显下降,并与疾病活动密切相关,两群细胞的失衡可能在SLE发病机制中起重要的作用。Objective To determine the ratio of CD25 and IL- 17A cells in peripheral CD4＋T cells of new- onset patients with systemic lupus erythematosus（SLE） and to assess their clinical significance. Methods Fifteen new- onset patients with sys-temic lupus erythematosus, including 10 active cases and 5 inactive cases, and 10 healthy individuals were enrol ed in the study. The ratio of CD25 and IL- 17A cells in peripheral CD4＋T cells was analyzed by flow cytometry. Disease activity was assessed by systemic lupus erythematosus activity index（SLEDAI）. Results There was no significant difference in frequency of CD4＋CD25high T cells and Th17 cells between SLE patients and normal controls （P〉0.05）. The frequency of CD4＋CD25high T cells and Th17 cells was not correlated with SLEDAI scores of patients （P〉0.05）. The ratio of CD4＋CD25high T cells and Th17 cells in active SLE pa-tients was significantly lower than that in inactive patients and healthy controls （P〈0.05） and it was negatively correlated with SLEDAI scores（P〈0.05）. Conclusion The results indicate that the imbalance of Treg cells and Th17 cells may be involved in the pathogenesis of SLE.

关 键 词：红斑狼疮 系统性 调节性T细胞 TH17细胞 

分 类 号：R593.241[医药卫生—内科学]